Stock comparison
Amphastar Pharmaceuticals
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AMPH
Amphastar Pharmaceuticals
Market cap
$811.75M
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AMPH | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 69B | MTD |
| Benjamin Graham | 50C | 65B | MTD |
| Philip Fisher | 50C | 63C | MTD |
| Peter Lynch | 40D | 66B | MTD |
| Joel Greenblatt | 22F | 68B | MTD |
| Charlie Munger | 44D | 74B | MTD |
| Terry Smith | 50D | 70B | MTD |
Side-by-side metrics
| Metric | AMPH | MTD |
|---|---|---|
| Market cap | $811.75M | $22.29B |
| P/E (TTM) | 10.6x | 25.3x |
| EV/EBIT | 5.1x | 21.6x |
| ROIC (TTM) | 6.02% | 36.09% |
| Gross margin | 47.34% | 57.79% |
| Net margin | 11.0% | 21.4% |
| Revenue CAGR 5y | 13.24% | 2.01% |
| EPS CAGR 5y | 12.74% | 6.12% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AMPH leads on
- Revenue CAGR 5y13.24%vs 2.01%+85%
- EV/EBIT5.1xvs 21.6x+76%
- P/E (TTM)10.6xvs 25.3x+58%
- EPS CAGR 5y12.74%vs 6.12%+52%
MTD leads on
- Debt / Equity-vs 0.1x+100%
- Market cap$22.29Bvs $811.75M+96%
- ROIC (TTM)36.09%vs 6.02%+83%
- Net margin21.4%vs 11.0%+49%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.